Bauer takes role of president at Chemwerth
Formerly with Sandoz
Prior to joining ChemWerth, Bauer was vice president of business development and licensing at Sandoz, a position that he held for five years beginning in 2005. At Sandoz, Bauer managed the US generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement.
Before Sandoz, Bauer worked at Eon Labs, a generic pharmaceutical company acquired by Sandoz in 2005. In total, Bauer has 18 years’ experience in the pharmaceutical and medical device industries.
ChemWerth was founded in 1982 to supply the emerging generic pharmaceutical industry with sources of high quality APIs. The firm represents numerous US FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.
You may also like
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia
AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
Pharmaceutical
ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research
ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine